Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Google recently published a guide outlining eight essential design patterns for multi-agent systems, ranging from sequential ...

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, ...

Abstract: In recent years, the domain of robotic manipulation has broadened its focus from rigid objects to more complex tasks involving deformable objects. Compared to rigid bodies, the model-based ...